Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2019-10-08 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Roadshow Montreal
Investor Presentation Classification · 98% confidence The document text contains slides from a presentation titled "Roadshow Montreal" dated October 8, 2019. It discusses the company's portfolio, market dynamics, growth drivers, shareholder return, and provides a "Financial Review Q2/19" with key financials and segment updates. The content is strategic, forward-looking, and summarizes performance, which is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief announcement of a report (RPA/RNS). The structure and content strongly align with materials prepared for investors during roadshows or presentations.
2019-10-08 English
Exane BNP Paribas – IR Insight Day
Investor Presentation Classification · 99% confidence The document is titled 'Exane BNP Paribas – IR Insight Day 2019' and contains extensive slides detailing the company's business segments (Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed), financial performance highlights (Sales, TSR, Growth Targets), and updates on Q2/19 results and outlooks. This format—a detailed presentation deck used to communicate strategy, performance, and future guidance to investors—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER).
2019-10-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' as of 30.09.2019. It details a capital measure (Conditional capital increase) and provides the new total number of voting rights (557,201,495). This type of announcement, concerning the total number of shares/voting rights, is a specific regulatory disclosure. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a specific regulatory filing or a notification related to capital structure changes. Since the core content is the announcement of the total voting rights following a capital measure, it fits best under the general 'Regulatory Filings' (RNS) category as a specific regulatory disclosure that doesn't have a more precise code among the options, although it is related to capital changes. However, given the specific nature of reporting total voting rights, which often accompanies capital changes or is required by securities laws (like WpHG mentioned here), it is a mandatory regulatory disclosure. Since there is no specific code for 'Total Voting Rights Announcement', RNS is the most appropriate fallback for a mandatory regulatory disclosure not covered elsewhere. It is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), as it reports the total outstanding rights, not individual transactions/holdings crossing thresholds.
2019-09-30 English
Berenberg and Goldman Sachs – 8th German Corporate Conference
Investor Presentation Classification · 99% confidence The document is a presentation containing financial highlights, operational updates, market dynamics, and growth targets for Fresenius Group and its segments (Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed). Specifically, it details 'Financial Review Q2/19' and 'Q2/19 Highlights', including key financial tables and segment performance reviews for the second quarter of 2019. This structure—a comprehensive review of a specific interim financial period—is characteristic of an Interim/Quarterly Report (IR). While it is presented as a presentation (which might suggest IP), the depth and focus on detailed quarterly financial results and segment performance strongly align with the content typically found in a formal Interim Report, rather than just a high-level Investor Presentation.
2019-09-24 English
Baader Investment Conference 2019
Investor Presentation Classification · 100% confidence The document is a presentation titled "Baader Investment Conference 2019" dated September 23, 2019. It contains detailed financial highlights, segment updates (Fresenius Medical Care, Kabi, Helios, Vamed), growth targets for 2020-2023, and specific financial results for Q2/19. This structure—a presentation format summarizing performance, strategy, and outlook for investors—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief announcement of a report (RPA/RNS). It is a comprehensive deck designed for investor engagement.
2019-09-23 English
Bank of America Merrill Lynch – Global Healthcare Conference
Investor Presentation Classification · 98% confidence The document text explicitly references a presentation given at the 'Bank of America Merrill Lynch Global Healthcare Conference 2019' and contains slides detailing company performance, segment updates (Fresenius Medical Care, Kabi, Helios, Vamed), financial highlights for 'Q2/19', and forward-looking statements. This structure—a presentation deck used to communicate results and strategy to investors, often following an earnings announcement—is characteristic of an Investor Presentation (IP). It is not a full Annual Report (10-K), a standalone Audit Report (AR), or just a brief Earnings Release (ER), as it contains significant detail and strategic context typical of a presentation given at an investor conference.
2019-09-19 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.